{"filings":[{"id":590681,"accession_number":"0001555280-26-000029","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2026-05-21T23:35:48+00:00","items":["5.02","5.07"],"status":"ready","headline":"Zoetis director Louise Parent retires; annual meeting approves all management proposals","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Director Louise M. Parent retired effective May 20, 2026 under company retirement policy.","All 12 director nominees elected with votes for ranging from 330M to 356M.","Say-on-pay approved with 306.3M for vs 51.6M against (85.8% support).","Shareholders voted 353.4M for holding say-on-pay every year.","Shareholder proposal to permit written consent failed: 167.3M for, 190.2M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":33085480000.000004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":554996,"accession_number":"0001555280-26-000026","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2026-05-20T20:23:35+00:00","items":["7.01","9.01"],"status":"ready","headline":"Zoetis declares Q3 2026 dividend of $0.53 per share","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly dividend set at $0.53 per share for Q3 2026.","Payable on September 1, 2026; record date July 20, 2026.","Dividend marks continued quarterly payout to common stockholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":33085480000.000004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93606,"accession_number":"0001555280-26-000021","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zoetis Q1 revenue flat organic; cuts FY 2026 guidance on softer demand and competition","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.3B, +3% reported but flat organic; net income $601M ($1.42 EPS), flat YoY.","Adjusted net income $646M ($1.53 EPS), +2% reported, +1% organic; guidance cut: FY rev $9.68-9.96B (2-5% organic growth).","U.S. segment revenue down 8% on competitive pressure and macro price sensitivity; International up 10% organic.","Acquisition of Neogen animal genomics business announced March 2, expected to close H2 2026.","Pipeline includes >12 potential blockbusters; recent approvals in Canada, Thailand, Japan."],"consensus_eps_estimate":null,"consensus_eps_actual":1.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":2262000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":33085480000.000004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105376,"accession_number":"0001555280-26-000008","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zoetis Q4 2025 revenue $2.4B (+3%), EPS $1.37; FY26 guidance $9.825-10.025B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $2.4B (+3% reported, +4% organic); net income $603M (EPS $1.37, +6%).","Full year 2025 revenue $9.5B (+2% reported, +6% organic); adjusted EPS $6.41 (+8% reported).","FY 2026 guidance: revenue $9.825-10.025B (organic growth 3-5%); adjusted EPS $7.00-7.10.","U.S. segment revenue flat organically; International up 7% organic driven by parasiticide and livestock growth.","Acquired VPG in UK/Ireland; received approvals for long-acting OA pain mAbs Lenivia (dog) and Portela (cat) in Canada/EU."],"consensus_eps_estimate":null,"consensus_eps_actual":6.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":9467000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":33085480000.000004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105375,"accession_number":"0001555280-26-000003","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Zoetis declares Q2 2026 dividend of $0.53 per share","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Dividend of $0.53 per share declared for second quarter of 2026.","Payable on June 2, 2026 to holders of record as of April 20, 2026.","Quarterly dividend rate unchanged from prior quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":33085480000.000004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121665,"accession_number":"0001193125-25-324853","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["1.01","2.03","3.02","7.01","9.01"],"status":"ready","headline":"Zoetis issues $2B of 0.25% convertible notes due 2029; proceeds for stock buyback and capped calls","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Aggregate principal $2.0B (including $250M option exercised); 0.25% semi-annual interest; matures June 15, 2029.","Initial conversion price ~$148.20/share, representing a 22.5% premium to December 15, 2025 closing price.","Capped calls with six counterparties cover ~13.5M shares; cap price $211.715/share to offset dilution.","Net proceeds ~$1.9696B: $186.6M for capped calls, $248M for concurrent share repurchases, remainder ~$1.535B for additional buybacks by Q1 2026.","Existing $6B share repurchase program used; technical provision in revolving credit facility waived to permit early conversions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":33085480000.000004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121664,"accession_number":"0001555280-25-000282","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Zoetis declares $0.53 per share quarterly dividend for Q1 2026","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Zoetis declared a quarterly dividend of $0.53 per share for Q1 2026.","Record date is January 20, 2026; payment date is March 3, 2026.","Dividend amount remains unchanged from the prior quarterly rate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":33085480000.000004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121663,"accession_number":"0001555280-25-000280","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2025-12-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Zoetis posts Innovation Webcast presentation; no material financial details provided","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Innovation Webcast scheduled for Dec 2, 2025 at 8:30 a.m. ET.","Presentation filed as Exhibit 99.1 but content not fully available in filing text.","No specific financial guidance, product updates, or operational metrics released.","Investors directed to presentation for potential pipeline or strategy details."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":33085480000.000004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121662,"accession_number":"0001555280-25-000272","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zoetis Q3 adjusted EPS $1.70 (+8%); revenue $2.4B (+4% organic); FY guidance narrowed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $2.4B (+1% reported; +4% organic operational); net income $721M, $1.63 diluted EPS (+9% YoY).","Adjusted net income $754M, $1.70 adjusted diluted EPS (+8% reported; +12% organic operational).","U.S. segment revenue $1.3B (-2% reported, +3% organic); International $1.1B (+3% reported, +6% organic).","Updated FY2025 revenue guidance $9.400-9.475B (5.5-6.5% organic growth); adjusted EPS $6.30-6.40 maintained.","Regulatory milestones: Lenivia approved in Canada/EU for canine OA pain; Portela approved in EU for feline OA."],"consensus_eps_estimate":null,"consensus_eps_actual":4.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":7080000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":33085480000.000004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121661,"accession_number":"0001555280-25-000266","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Zoetis appoints Stephanie Tilenius to Board, effective Dec 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stephanie Tilenius appointed to Zoetis Board, effective December 1, 2025.","Board size increases from 12 to 13 members upon her appointment.","No arrangements with third parties or related party transactions reported.","Ms. Tilenius will participate in standard non-employee director compensation program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":33085480000.000004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121660,"accession_number":"0001555280-25-000264","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2025-10-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Zoetis declares $0.50 per share Q4 dividend, payable Dec 2, 2025","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Dividend of $0.50 per share declared for Q4 2025.","Payable on December 2, 2025, to holders of record as of October 31, 2025.","Quarterly dividend rate unchanged from prior quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":33085480000.000004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138337,"accession_number":"0001193125-25-189772","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2025-08-27T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"Zoetis enters $1.25B revolver, replaces 2022 facility; can increase to $1.75B","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New five-year $1.25B senior unsecured revolving credit facility, maturing August 2030.","Facility replaces existing $1.25B credit agreement scheduled to expire December 2027.","JPMorgan Chase Bank, N.A. acts as administrative agent; Barclays, Bank of America, Citibank, MUFG as syndication agents.","Loans bear interest at base rate or term SOFR plus applicable margin based on credit ratings.","Financial covenant requires not exceeding a maximum total leverage ratio; customary affirmative/negative covenants apply."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":33085480000.000004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138336,"accession_number":"0001193125-25-182451","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Zoetis issues $1.85B in senior notes: $850M at 4.150% due 2028, $1B at 5.000% due 2035","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $850M 4.150% Senior Notes due 2028 and $1B 5.000% Senior Notes due 2035.","Notes issued under existing indenture with Deutsche Bank Trust Company Americas as trustee.","Underwriters include Barclays, BofA, Citigroup, J.P. Morgan, and MUFG Securities.","Offering registered on Form S-3; no specific use of proceeds disclosed in the 8-K.","Debt issuance increases total long-term debt by $1.85B; interest expense will rise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":33085480000.000004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138335,"accession_number":"0001555280-25-000259","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zoetis Q2 revenue $2.5B (+4% reported, +8% organic); raises FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported net income $718M ($1.61 diluted EPS), up 15% YoY; adjusted EPS $1.76, up 13%.","U.S. segment revenue $1.4B (+4% reported, +7% organic); companion animal product sales up 9%.","International segment revenue $1.1B (+3% reported, +9% organic); livestock sales up 10% organic.","Raised FY2025 revenue guidance to $9.45-9.60B (organic growth 6.5-8.0%); adjusted EPS $6.30-6.40.","Simparica Trio gained new label in Japan; avian influenza vaccine conditionally licensed for U.S. dairy cattle."],"consensus_eps_estimate":null,"consensus_eps_actual":3.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":4680000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":33085480000.000004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155783,"accession_number":"0001555280-25-000213","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Zoetis appoints Mark Stetter to board; Robert Scully retires","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert Scully retired from Zoetis board effective May 21, 2025, under director retirement policy.","Mark Stetter elected to board at annual meeting; received 371.2M votes for, 0.4M against.","Shareholders approved executive compensation (334.2M for, 35.2M against) and ratified KPMG as auditor (384.8M for, 7.6M against).","Shareholder proposal to improve special meeting process failed with 50.4M for vs. 320.7M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":33085480000.000004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155782,"accession_number":"0001555280-25-000209","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Zoetis declares $0.50/share quarterly dividend for Q3 2025","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Dividend of $0.500 per share declared for third quarter 2025.","Payable on September 3, 2025 to stockholders of record as of July 18, 2025.","Routine quarterly dividend declaration with no change in amount indicated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":33085480000.000004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155781,"accession_number":"0001555280-25-000201","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zoetis Q1 2025 revenue $2.2B (+9% organic), adj EPS $1.48; affirms 6-8% organic growth for FY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.2B (+1% reported, +9% organic operational); net income $631M, diluted EPS $1.41.","Adjusted net income $662M, adj diluted EPS $1.48; +6% organic operational growth YoY.","U.S. segment revenue $1.2B (+6% organic); International $1.0B (+11% organic on operational basis).","FY25 guidance: revenue $9.425-9.575B (6-8% organic); adj diluted EPS $6.20-6.30, reflecting FX and tariffs.","Simparica Trio gains U.S. flea tapeworm label; avian influenza vaccine conditional license in U.S./Canada."],"consensus_eps_estimate":null,"consensus_eps_actual":1.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":2220000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":33085480000.000004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174258,"accession_number":"0001555280-25-000100","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zoetis Q4 revenue $2.3B (+5%), adj. EPS $1.40; FY2025 guidance organic growth 6-8%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue $2.3B (+5% reported, +9% organic operational); reported EPS $1.29, adjusted EPS $1.40.","FY 2024 revenue $9.3B (+8% reported, +12% organic); reported EPS $5.47, adjusted EPS $5.92.","U.S. segment revenue $1.3B (+4%); companion animal +7% on Simparica Trio, Apoquel, Librela; livestock -8% on MFA divestiture.","International segment revenue $1.0B (+6% reported, +10% operational); companion animal +11%, livestock flat.","FY 2025 guidance: revenue $9.225-9.375B, adjusted EPS $6.00-6.10, organic operational revenue growth 6-8%."],"consensus_eps_estimate":null,"consensus_eps_actual":5.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":9256000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":33085480000.000004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174257,"accession_number":"0001555280-25-000022","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Zoetis declares $0.500 per share quarterly dividend for Q2 2025","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Dividend of $0.500 per share declared for second quarter 2025.","Payable on June 3, 2025 to holders of record as of April 21, 2025.","Quarterly dividend rate unchanged from prior quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":33085480000.000004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174256,"accession_number":"0001555280-25-000005","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Zoetis presents at J.P. Morgan Healthcare Conference on Jan 14, 2025; focus on growth strategy","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Members of Zoetis management to present at 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025.","Presentation titled 'A Best in Breed Growth Strategy' emphasizes growth focus.","No specific financial data or guidance disclosed in the furnished exhibit; only cover page included."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":33085480000.000004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191186,"accession_number":"0001555280-24-000342","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2024-12-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Zoetis declares $0.500 quarterly dividend payable March 4, 2025","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Dividend of $0.500 per share for Q1 2025 declared on Dec 12, 2024.","Payable March 4, 2025 to shareholders of record as of Jan 21, 2025.","Quarterly dividend maintained at $0.500; no change from prior period.","Record date set at Jan 21, 2025 for common stock (ZTS)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":33085480000.000004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191185,"accession_number":"0001555280-24-000335","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Zoetis announces leadership reshuffle: CTO Mamilli leaving, new CCO and US President appointed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Wafaa Mamilli (EVP, Chief Digital & Technology Officer) to leave early 2025 for external opportunity; Keith Sarbaugh promoted to EVP and Chief Digital & Technology Officer, effective immediately.","Jamie Brannan appointed to new role of EVP and Chief Commercial Officer, overseeing all global commercial markets including US and International operations.","Ester Banque (EVP, President US Operations) is leaving the company; Jared Shriver promoted to President US Operations, reporting to Brannan, effective immediately.","All changes effective immediately except Mamilli's departure, which occurs in early 2025; Banque will serve in advisory capacity until then."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":33085480000.000004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191184,"accession_number":"0001555280-24-000330","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zoetis Q3 revenue $2.4B (+11%); adjusted EPS $1.58; FY guidance raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.4B, +11% reported (+14% operational); GAAP EPS $1.50 (+16% YoY).","Adjusted net income $716M, adjusted EPS $1.58 (+16% reported, +17% operational).","U.S. segment revenue $1.3B (+15%) led by mAbs (Librela, Solensia) and Simparica Trio.","International segment revenue $1.0B (+7% reported, +13% operational) with broad product strength.","FY2024 guidance raised: revenue $9.20-9.30B, adjusted EPS $5.86-5.92, operational growth 10-11%."],"consensus_eps_estimate":null,"consensus_eps_actual":4.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":6939000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":33085480000.000004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191183,"accession_number":"0001555280-24-000326","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2024-10-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Zoetis declares Q4 2024 dividend of $0.432 per share","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Dividend of $0.432/share declared for Q4 2024, payable Dec 3, 2024.","Record date for dividend is Oct 31, 2024.","Board of Directors approved the dividend on Oct 10, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":33085480000.000004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207664,"accession_number":"0001555280-24-000295","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zoetis Q2 2024: revenue $2.4B (+11% op), adj EPS $1.56 (+20% op), raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.4B, +8% reported / +11% operational; U.S. +12%, International +10% op.","GAAP net income $624M (-7%), diluted EPS $1.37 (-6%).","Adjusted net income $711M (+9% reported, +18% operational), adjusted diluted EPS $1.56 (+11% reported, +20% operational).","FY2024 guidance raised: revenue $9.100-9.250B, adj EPS $5.78-5.88; op rev growth 9-11%, op adj NI growth 13.5-15.5%.","Growth led by mAb OA pain products Librela/Solensia, Simparica Trio, and dermatology portfolio Apoquel/Cytopoint."],"consensus_eps_estimate":null,"consensus_eps_actual":2.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":4551000000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":33085480000.000004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207663,"accession_number":"0001555280-24-000290","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Zoetis announces $6B share repurchase program, replacing $3.5B program expected to finish in 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved up to $6 billion in share repurchases with no expiration date.","Previous $3.5 billion program (Dec 2021) expected to be completed in 2024.","Repurchases may be executed via open market or private transactions; program does not obligate purchases.","Authorization may be terminated, increased, or decreased by the Board at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":33085480000.000004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225133,"accession_number":"0001555280-24-000262","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Zoetis announces separation from EVP, General Counsel Heidi Chen; consulting fee $350K","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Heidi Chen steps down as EVP, General Counsel effective April 16, 2024; remains non-officer employee through July 16, 2024.","After July 16, will serve as non-employee consultant through Dec 31, 2024, earning $350,000 consulting fee.","Eligible for severance benefits under Zoetis Executive Severance Plan subject to release and restrictive covenants.","Transition period includes continued base salary and benefits; consulting duties limited to 20% of prior service level."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":33085480000.000004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225132,"accession_number":"0001555280-24-000257","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"Zoetis shareholders approve officer exculpation; director Linda Rhodes retires","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Director Linda Rhodes retired from the board effective May 21, 2024, per the retirement policy.","Shareholders approved officer exculpation amendment (345.3M for, 40.7M against), limiting officer liability.","All 12 director nominees elected; say-on-pay passed with 351.1M votes for.","Shareholder proposal on director resignation policy defeated (53.8M for, 331.8M against).","KPMG ratified as independent auditor for 2024 with 401.4M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":33085480000.000004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225131,"accession_number":"0001555280-24-000252","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2024-05-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Zoetis declares Q3 2024 dividend of $0.432 per share, payable September 4","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly dividend of $0.432 per share declared for Q3 2024, unchanged from previous quarter.","Payable on September 4, 2024 to holders of record as of July 18, 2024.","Routine quarterly dividend declaration; no special or increased dividend."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":33085480000.000004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225130,"accession_number":"0001555280-24-000247","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zoetis Q1 revenue $2.2B (+10% reported, +12% operational); adj EPS $1.38, +5% reported","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported net income $599M ($1.31 diluted EPS) +9%; adjusted net income $634M ($1.38 adj EPS) +5% reported, +17% operational.","US segment revenue $1.2B (+16%), driven by Simparica Trio, Apoquel, Cytopoint, Librela, Solensia.","International segment revenue $1.0B (+3% reported, +8% operational); companion animal +14% operational.","FY 2024 guidance raised: revenue $9.05-9.20B, reported EPS $5.34-5.44, adj EPS $5.71-5.81; operational growth 8.5-10.5%.","Company to sell MFA portfolio and buy a manufacturing site in Australia for vaccine development."],"consensus_eps_estimate":null,"consensus_eps_actual":1.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":2190000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":33085480000.000004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225129,"accession_number":"0001555280-24-000237","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2024-04-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Zoetis EVP, General Counsel Heidi C. Chen to step down; interim named","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Heidi C. Chen to cease as EVP, General Counsel and Corporate Secretary effective April 16, 2024.","She will serve as employee advisor through July 16, 2024, then as non-employee consultant.","Roxanne Lagano, EVP CHRO and Global Operations, appointed interim General Counsel and Corporate Secretary.","Company conducting search for permanent replacement, considering internal and external candidates.","Chen eligible for separation benefits under Executive Severance Plan and retirement-eligible benefits."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":33085480000.000004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225128,"accession_number":"0001555280-24-000197","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2024-04-01T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Zoetis appoints Gavin Hattersley to Board, increases size to 13","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Gavin D.K. Hattersley appointed to Zoetis Board effective April 1, 2024.","Board size increased from 12 to 13; Hattersley joins Corporate Governance and Sustainability Committee.","No related-party transactions or third-party arrangements in connection with appointment.","Hattersley eligible for standard non-employee director compensation and indemnification agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":33085480000.000004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244352,"accession_number":"0001555280-24-000141","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2024-02-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zoetis Q4 2023 revenue $2.2B (+8%), adj. EPS $1.24; FY2024 guidance $9.075-9.225B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $2.2B (+8% reported & operational); net income $525M ($1.14 diluted EPS), up 14% and 15% respectively.","Adjusted net income Q4 $569M ($1.24 diluted EPS), up 6% operational.","FY 2023 revenue $8.5B (+6% reported, +7% operational); net income $2.3B ($5.07 diluted EPS).","FY 2024 guidance: revenue $9.075-9.225B (operational growth 7-9%); adjusted diluted EPS $5.74-5.84.","Key growth drivers: Librela, Simparica Trio, dermatology; new approvals for Solensia in Brazil and Simparica Trio in China."],"consensus_eps_estimate":null,"consensus_eps_actual":5.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":8544000000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":33085480000.000004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244351,"accession_number":"0001555280-24-000030","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2024-02-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Zoetis declares Q2 2024 dividend of $0.432 per share","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly dividend of $0.432 per share declared for Q2 2024.","Payable June 4, 2024 to holders of record on April 19, 2024.","Dividend continues at the same quarterly rate as the prior quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":33085480000.000004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261776,"accession_number":"0001555280-23-000255","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2023-12-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Zoetis declares Q1 2024 dividend of $0.432 per share","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Dividend of $0.432 per share declared for Q1 2024.","Payable March 1, 2024 to holders of record as of Jan 19, 2024.","Dividend amount unchanged from prior quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":33085480000.000004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261775,"accession_number":"0001555280-23-000245","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zoetis Q3 revenue $2.2B (+8% operational), EPS $1.29; narrows FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.2B, up 7% reported / 8% operational; net income $596M ($1.29 EPS), +13%/+14%.","Adjusted net income $629M ($1.36 EPS), up 11% reported / 13% operational.","U.S. revenue +8% to $1.174B; companion animal +11%, livestock -2%.","International revenue +8% operational to $956M; companion animal +12% operational.","Full-year revenue guidance narrowed to $8.475-$8.55B (6.5%-7.5% operational growth); adj. EPS $5.38-$5.43."],"consensus_eps_estimate":null,"consensus_eps_actual":3.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":6331000000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":33085480000.000004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261774,"accession_number":"0001555280-23-000236","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2023-10-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Zoetis declares Q4 2023 dividend of $0.375 per share","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Dividend of $0.375 per share declared by Board on October 12, 2023.","Payable on December 1, 2023 to holders of record as of November 1, 2023.","No change from prior quarterly dividend rate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":33085480000.000004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278965,"accession_number":"0001555280-23-000203","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zoetis Q2 revenue $2.2B +6% reported, +9% operational; EPS $1.45, adj. EPS $1.41; maintains FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.2B, +6% reported, +9% operational; net income $671M ($1.45 EPS) +27%/29%.","Adjusted net income $652M ($1.41 adj. EPS) +15%/18% reported.","U.S. segment rev $1.165B +7%; intl. $995M +6% reported, +11% operational.","Companion animal portfolio +11% operational; livestock +4% operational.","FY2023 guidance: rev $8.50-8.65B, adj. net inc. $2.50-2.55B; operational growth maintained."],"consensus_eps_estimate":null,"consensus_eps_actual":2.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":4180000000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":33085480000.000004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297281,"accession_number":"0001555280-23-000166","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2023-05-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Zoetis Investor Day targets mid-to-high single-digit revenue growth, $1B+ peak OA pain franchise","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual revenue growth target of mid-to-high single digits over next 3-5 years.","Osteoarthritis pain franchise expected to exceed $1B in peak sales.","Existing billion-dollar franchises in dermatology and pet parasiticides to be expanded.","Drive ROIC accretion and margin improvement through revenue growth and global scale leverage.","Disciplined capital allocation balancing investments and return of capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":33085480000.000004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297280,"accession_number":"0001555280-23-000159","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2023-05-19T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Zoetis shareholders approve special meeting right amendment at 2023 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special Meeting Amendment to Restated Certificate approved with 364M votes for, 2M against, 35.9M abstentions.","Board adopted conforming bylaw amendments detailing shareholder procedures for calling special meetings.","All eight director nominees elected, including Kristin Peck, with votes for ranging 393-399M.","Non-binding advisory vote on executive compensation approved (374.4M for, 27.1M against).","Shareholder proposal on special meetings also narrowly approved (209.3M for, 189.9M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":33085480000.000004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297279,"accession_number":"0001555280-23-000156","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Zoetis declares $0.375 quarterly dividend for Q3 2023","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Dividend of $0.375 per share declared for third quarter 2023.","Payable on September 1, 2023 to holders of record as of July 21, 2023.","Represents a regular quarterly dividend; no change from prior quarter indicated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":33085480000.000004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297278,"accession_number":"0001555280-23-000148","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zoetis Q1 revenue $2.0B (+1% reported, +4% operational); adj. EPS $1.31, down 1% operationally","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported net income $552M ($1.19 diluted EPS), down 7% and 6% YoY respectively.","Adjusted net income $607M ($1.31 diluted EPS); adjusted diluted EPS down 1% operationally.","International segment revenue grew 10% operationally; U.S. segment revenue declined 1%.","Full-year 2023 guidance maintained: revenue $8.575-8.725B, adj. diluted EPS $5.34-5.44.","U.S. companion animal sales fell 7% due to distributor de-stocking; livestock sales up 15%."],"consensus_eps_estimate":null,"consensus_eps_actual":1.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":2000000000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":33085480000.000004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317642,"accession_number":"0001555280-23-000072","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2023-02-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zoetis Q4 revenue $2.0B (+9% operational); adj. EPS $1.15; FY23 guide $8.575-8.725B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $2.0B (+4% reported, +9% operational); net income $461M ($0.99 EPS); adj. net income $539M ($1.15 adj. EPS).","Full year 2022 revenue $8.1B (+4% reported, +8% operational); adj. net income $2.3B ($4.88 adj. EPS).","U.S. segment revenue $1.112B (+7%), driven by Simparica Trio and dermatology brands Apoquel and Cytopoint.","International segment revenue $901M (flat reported, +12% operational), led by parasiticides and dermatology.","FY23 guidance: revenue $8.575-8.725B (6-8% operational growth); adj. diluted EPS $5.34-5.44."],"consensus_eps_estimate":null,"consensus_eps_actual":4.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":8080000000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":33085480000.000004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317641,"accession_number":"0001555280-23-000023","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2023-02-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Zoetis declares $0.375/share quarterly dividend for Q2 2023","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Dividend of $0.375 per share declared for second quarter 2023.","Payable on June 1, 2023 to holders of record as of April 21, 2023.","Declaration made on February 8, 2023 and disclosed via Form 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":33085480000.000004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317640,"accession_number":"0001104659-23-011475","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2023-02-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Zoetis fires EVP Glenn David for undisclosed relationship; interim head named","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Glenn David, EVP and Group President of U.S. Operations and Global Diagnostics, terminated Feb 5 for violating company policy (consensual personal relationship, failure to disclose).","David forfeits severance benefits and future equity vesting as a result of termination for cause.","William ('Chip') Dorsey, VP Finance, named interim head of U.S. Operations and Global Diagnostics; permanent search underway.","Company states conduct did not impact consolidated financial statements or internal controls over financial reporting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":33085480000.000004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335880,"accession_number":"0001555280-22-000287","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2022-12-21T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"Zoetis enters into $1.0B revolving credit facility, replaces prior agreement","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New five-year $1.0B senior unsecured revolving credit facility with a syndicate of banks; JPMorgan as administrative agent.","Facility replaces prior $1.0B credit agreement that was set to expire in Dec 2023.","Company has right to increase commitments to up to $1.5B subject to conditions.","Interest rates based on SOFR or base rate plus margin; facility fee based on credit ratings.","Financial covenant requires maximum total leverage ratio."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":33085480000.000004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335879,"accession_number":"0001555280-22-000284","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2022-12-08T23:59:59+00:00","items":["5.03","7.01","9.01"],"status":"ready","headline":"Zoetis declares $0.375/share Q1 2023 dividend; payable March 1","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Dividend of $0.375 per common share for Q1 2023, payable March 1, 2023, record date January 20, 2023.","Board amended bylaws to align with SEC universal proxy rules, effective December 8, 2022.","New bylaw requires nominating shareholders to solicit proxies from 67% of outstanding shares for non-management director nominees.","Shareholder nominations will be disregarded if the nominating shareholder fails to comply with Rule 14a-19 requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":33085480000.000004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335878,"accession_number":"0001104659-22-119521","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2022-11-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Zoetis issues $1.35B in senior notes: $600M at 5.400% due 2025 and $750M at 5.600% due 2032","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $600M of 5.400% Senior Notes due 2025 and $750M of 5.600% Senior Notes due 2032.","Underwriting agreement dated Nov 8, 2022; closing on Nov 16, 2022.","Underwriters include Barclays, BofA Securities, Citigroup, J.P. Morgan, MUFG.","Notes issued under existing indenture with Deutsche Bank Trust Company Americas as trustee.","Offering registered on Form S-3 (File No. 333-266591)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":33085480000.000004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335877,"accession_number":"0001555280-22-000274","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zoetis Q3 2022 revenue $2.0B (+1%), net income $529M; cuts FY 2022 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.0B, +1% reported (+5% operational); net income $529M ($1.13 diluted EPS), down 4% and 3%.","Adjusted net income $566M, adjusted diluted EPS $1.21, down 5% reported but +2% operational.","FY 2022 guidance lowered: revenue $8.0-8.075B, diluted EPS $4.51-4.59 reported, $4.83-4.90 adjusted.","U.S. segment revenue $1.09B (+2%); International $889M (-2% reported, +8% operational).","Guidance cut due to supply constraints, veterinary workforce challenges, and negative FX impact."],"consensus_eps_estimate":null,"consensus_eps_actual":3.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":6040000000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":33085480000.000004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335876,"accession_number":"0001555280-22-000266","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2022-10-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Zoetis appoints Glenn David as EVP of U.S. Ops, Diagnostics, BioDevices; Jamie Brannan to International Ops","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Glenn David becomes EVP and Group President, U.S. Operations, Global Diagnostics and BioDevices effective Nov 1, 2022.","Jamie Brannan appointed EVP and Group President, International Operations and Aquaculture (PHARMAQ) effective same date.","Wafaa Mamilli, Chief Digital and Technology Officer, adds oversight of China, Brazil and Precision Animal Health."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":33085480000.000004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-10-25T23:59:59+00:00|335876"}